Therapy with EnteraGam ® resulted in management of frequent loose stools and abdominal discomfort 1 39-Year-Old Caucasian Female: Summary of Case Presentation Abbreviated medical history: Antiphospholipid antibody syndrome, methylenetetrahydrofolate reductase homozygous, and HSV-1.
EnteraGam ® 5 g QID therapy initiated.
Initial symptoms: Abdominal discomfort, multiple bloody diarrhea episodes.
Frequent loose stools managed within 48 hours.
Initial treatments: Fidaxomicin and vancomycin.~1
week after stopping EnteraGam ® diarrhea returns.
Negative for CDI.
Cholecystectomy for acute cholecystitis. Fidaxomicin for diarrhea and recurrent CDI.
EnteraGam ® resumed, resulting in management of frequent loose stools and abdominal discomfort.
Still symptomatic. Negative for CDI. Could not tolerate cholestyramine or antidiarrheals. No clinical change with low-fat diet.
Patient continued with EnteraGam ® 5 g BID. Patient able to return to work.
Diagnosed with post-infectious irritable bowel syndrome (PI-IBS). Unable to work.
One month later, EnteraGam ® reduced to 5 g QD.
No further C difficile relapses.
EnteraGam ® improved the patient's quality of life and allowed her to return to work. 1
Case #1
EnteraGam ® managed the patient's PI-IBS symptoms 1
57-Year-Old Caucasian Female: Summary of Case Presentation
Abbreviated medical history: Hypothyroidism, hypercholesterolemia, angioplasty for coronary artery disease (x3), neuropathy, and idiopathic gastroparesis.
EnteraGam ® 5 g BID therapy initiated.
Concurrent medications: Levothyroxine, furosemide, duloxetine, pravastatin, and aspirin.
Patient noticed better management of her condition within a few days.
Initial treatments:
Antibiotics for flu-like symptoms, wheezing, and possible pneumonia.
Treated with metronidazole one month later for urinary tract infection. Patient reported some constipation. Diarrhea (7 watery bowel movements/day) with mucus and blood for 2 months. Treated with ciprofloxacin and metronidazole.
EnteraGam ® reduced to 5 g QD to avoid potential for constipation.
Hospitalized for 5 days. Treated with metronidazole and vancomycin for positive CDI. Readmitted for dehydration. Continued vancomycin for positive CDI postdischarge.
Patient continues to report normal regulation of bowel habits. • "In both cases, the use of SBI [EnteraGam ® ] was able to…manage the patient's PI-IBS symptoms which included chronic and frequent loose stools as well as abdominal discomfort, allowing the patients to have normal bowel habits and improved quality of life."
• "Because SBI [EnteraGam ® ] is intended for use to manage IBS-D and has the added ability to bind to C difficile toxins, it may have a valuable role in both the management of PI-IBS as well as binding of C difficile toxins A and B if reinfection occurs. This may help normalize the gut environment to allow normal flora to outgrow C difficile."
• "The outcomes of both cases reported in this manuscript suggest that there is a distinctive nutritional requirement for SBI [EnteraGam ® ] unique to patients with PI-IBS."
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